Understanding Tau Protein's Role in Alzheimer's Brain Connections

Tau oligomer conformers and synaptic vulnerability/resilience in AD and related disorders

['FUNDING_R01'] · UNIVERSITY OF TEXAS MED BR GALVESTON · NIH-11132926

This project aims to discover how specific forms of a protein called tau harm brain connections in Alzheimer's disease and related conditions, with the goal of finding ways to protect these connections.

Quick facts

Phase['FUNDING_R01']
Study typeNih_funding
SexAll
SponsorUNIVERSITY OF TEXAS MED BR GALVESTON (nih funded)
Locations1 site (GALVESTON, UNITED STATES)
Trial IDNIH-11132926 on ClinicalTrials.gov

What this research studies

Alzheimer's disease causes brain connections, known as synapses, to stop working correctly, and a protein called tau is believed to be a major factor. We are working to understand how different types of tau proteins, called conformers, specifically damage these vital connections. By studying individuals who show resilience to this damage despite having tau in their brains, we hope to uncover natural protective mechanisms. Our ultimate goal is to lay the groundwork for new treatments that can keep brain connections healthy in people affected by Alzheimer's and similar conditions.

Who could benefit from this research

Good fit: This foundational research is relevant for individuals interested in the basic biological mechanisms of Alzheimer's disease and related dementias, as it seeks to inform future treatment strategies.

Not a fit: Patients looking for immediate clinical trials or direct therapeutic interventions would not directly benefit from this early-stage, basic science project.

Why it matters

Potential benefit: If successful, this work could lead to the development of new therapies that protect brain synapses from tau protein damage, potentially slowing or preventing the progression of Alzheimer's disease.

How similar studies have performed: While the general role of tau in Alzheimer's is recognized, this specific focus on distinct tau conformers and mechanisms of synaptic resilience represents a novel and promising avenue for therapeutic discovery.

Where this research is happening

GALVESTON, UNITED STATES

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.

View on NIH RePORTER →

Conditions: Alzheimer disease dementia, Alzheimer syndrome, Alzheimer's Disease, Alzheimer's disease and related dementia, Alzheimer's disease and related disorders

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.